De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

TransCode Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

TransCode Therapeutics heeft een totaal eigen vermogen van $1.3M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $4.8M en $3.5M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsratio	n/a
Contant	US$3.35m
Aandelen	US$1.32m
Totaal verplichtingen	US$3.50m
Totaal activa	US$4.82m

Recente financiële gezondheidsupdates

Recent updates

TransCode Therapeutics reports Q2 results

Aug 15

TransCode files U.S. patent application for radiotherapy based cancer treatment

Jul 11

We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Apr 01

Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

Dec 15

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $4.4M ) RNAZ } overtreffen de korte termijn passiva ( $3.5M ).

Langlopende schulden: RNAZ heeft geen langlopende schulden.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: RNAZ is schuldenvrij.

Schuld verminderen: RNAZ heeft momenteel geen schulden, maar we kunnen geen vergelijking maken met 5 jaar geleden omdat we geen gegevens hebben over die periode.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: RNAZ heeft voldoende cash runway voor 3 maanden op basis van de laatst gerapporteerde vrije kasstroom, maar heeft sindsdien extra kapitaal opgehaald.

Voorspelling contante baan: Er wordt voorspeld dat RNAZ voldoende kasmiddelen zal hebben voor 2 maanden op basis van de vrije kasstroom schattingen, maar heeft sindsdien extra kapitaal opgehaald.

TransCode Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

TransCode Therapeutics, Inc. Receives Non-Compliance Letter from Staff of Nasdaq

TransCode Therapeutics Receives Deficiency Letters from the Listing Qualifications Department (The “Staff”) of the Nasdaq

TransCode Therapeutics Intends to File a Request for a Hearing on or before May 14, 2024, in Response to Non-Compliance with the Nasdaq Listing Rule 5550(a)(2)

TransCode Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Required for Continued Listing on The Nasdaq Capital Market

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on the Nasdaq Stock Market Subject to Conditions

TransCode Therapeutics Provides Non Compliance Update

Recent updates

TransCode Therapeutics, Inc. Receives Non-Compliance Letter from Staff of Nasdaq

TransCode Therapeutics, Inc. Announces First Patients Treated in Phase 1 Clinical Trial with First-In-Class Lead Therapeutic Candidate

TransCode Therapeutics Receives Deficiency Letters from the Listing Qualifications Department (The “Staff”) of the Nasdaq

TransCode Therapeutics, Inc. Announces Phase 1 Clinical Trial Initiation

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $3 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Reports Positive Data from First-In-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Intends to File a Request for a Hearing on or before May 14, 2024, in Response to Non-Compliance with the Nasdaq Listing Rule 5550(a)(2)

TransCode Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

TransCode Therapeutics, Inc. Announces Fda Clearance to Initiate Phase 1/2 Clinical Trial Withttx-Mc138 in Patients with Advanced Solid Tumors

TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.194863 million.

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.25 million.

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with Its Lead Candidate, TTX-MC138

TransCode Therapeutics, Inc. to Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Required for Continued Listing on The Nasdaq Capital Market

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on the Nasdaq Stock Market Subject to Conditions

Transcode Therapeutics, Inc. Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Leading Therapeutic Candidate, Tx-Mc138

TransCode Therapeutics, Inc. Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate,TTX-MC138

TransCode Therapeutics, Inc. Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial

TransCode Therapeutics Provides Non Compliance Update

TransCode Therapeutics Receives Delisting Determination Letter from Nasdaq Advising Not to Accept its Compliance Plan, and Denies its Request for an Extension

TransCode Therapeutics, Inc. Announces Publication of New Data Supporting Use of TTX-MC138 for Treatment of Metastatic Breast Cancer

New major risk - Shareholder dilution

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Lead Candidate, Tx-MC138, in Glioblastoma

TransCode Therapeutics Announces 1-For-20 Reverse Stock Split to Satisfy the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

TransCode Therapeutics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma

Transcode Therapeutics, Inc. Announces FDA Authorization to Proceed with First-In-Human Clinical Trial

Transcode Therapeutics Announces Eind Submission to Us Fda for Planned First-In-Human Clinical Trial in Patients with Advanced Solid Tumors

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with Its Lead Candidate, TTX-MC138

TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology

TransCode Therapeutics, Inc. Appoints Frank J. Slack to its Advisory Board

TransCode Therapeutics reports Q2 results

TransCode files U.S. patent application for radiotherapy based cancer treatment

Co-Founder recently bought US$55k worth of stock

TransCode Therapeutics, Inc. Acquires Option for Radiotheranostic Technology

TransCode Therapeutics, Inc., Annual General Meeting, Jun 22, 2022